ArticleCureus2025
Prevalence and Patterns of Dyslipidemia Among Patients With Rheumatoid Arthritis: A Retrospective Cohort Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDyslipidemia is a major comorbidity among rheumatoid arthritis (RA), leading to an increased risk of cardiovascular diseases (CVD). Despite its clinical significance, the prevalence and patterns of dyslipidemia in RA are understudied, specifically in diverse populations. Understanding these patterns is essential for developing specific interventions to reduce cardiovascular risk in this population.
objectiveThe objective of this study is to assess the prevalence and patterns of dyslipidemia among patients with RA in Dubai, examining lipid profile changes before, at, and after diagnosis and exploring associated demographic and laboratory factors that may contribute to cardiovascular risk.
methodsA retrospective cohort study was conducted using data from the Epic medical record system in the Rheumatology Department of Dubai Hospital, Dubai Health, Dubai, UAE, between January 2019 and December 2020, with two-year time frames. One hundred and four patients were included in the study. All were adults aged 21-65, and all their data demographics and laboratory variables were collected from the medical record.
resultsThe sample was predominantly female, middle-aged, obese, and Emirati. The prevalence of dyslipidemia among RA patients was 78 (75%) before RA diagnosis. Among those with dyslipidemia, elevated low-density lipoprotein (LDL) levels were the most common abnormality (55, 52.9%), followed by reduced high-density lipoprotein (HDL) levels (41, 39.4%). At the time of RA diagnosis, 76 (73.1%) had dyslipidemia, with 52 (50%) having predominantly low HDL levels. After RA diagnosis, 72 (69.2%) had dyslipidemia, with 44 (42.3%) having predominantly high LDL levels. Significant lipid abnormalities were observed in all three phases of the disease during the study. No significant association was found between dyslipidemia and demographic characteristics.
conclusionThis study showed the prevalence of dyslipidemia among RA patients in Dubai, highlighting the importance of monitoring lipid profiles in RA patients and effective treatment to reduce the risk of CVD in the population for better outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.